Advances in Hydrogel-Based Drug Delivery Systems for Parkinson's Disease

Neurochem Res. 2022 Aug;47(8):2129-2141. doi: 10.1007/s11064-022-03617-w. Epub 2022 May 20.

Abstract

Parkinson's disease (PD) is a common central nervous system disorder (CNS) characterized by cell loss in the substantia nigra. Severe loss of dopaminergic neurons and Lewy body formation with α-synuclein inclusions are the main neuropathological features of PD. There's currently no cure for PD, but treatments are available to help relieve the symptoms and maintain quality of life. However, the variety of clinically available therapeutic molecules is mainly limited to treating symptoms rather than halting or reversing disease progression via medical interventions. As an emerging drug carrier, hydrogels loaded with therapeutic agents and cells are attracting attention as an alternative and potentially more effective approach to managing PD. The current work highlights applications of hydrogel-based biomaterials in cell culture and disease modeling as carriers for cells, medicines, and proteins as PD therapeutic models.

Keywords: Biomaterials; Drug carrier; Hydrogels; Parkinson’s disease; Treatment.

Publication types

  • Review

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Hydrogels / therapeutic use
  • Parkinson Disease* / metabolism
  • Quality of Life
  • Substantia Nigra / metabolism
  • alpha-Synuclein / metabolism

Substances

  • Hydrogels
  • alpha-Synuclein